However, the clinical value of BCR repertoire analysis from peripheral blood memory B cells, as an accessible blood-based tool for intercepting the anti-tumor humoral response initiated in situ and predicting ICI treatment efficacy in MM, remains unexplored. The gene discussed is BCR; the disease is Miyoshi myopathy.